Keywords: retrovir, videx, switch, benefit, switching, hiv-infected, patients
RETROVIR TO VIDEX SWITCH BENEFIT
Article | 04 May 1992
Switching HIV-infected patients who have received treatment with Wellcome's Retrovir (zidovudine) for over 16 weeks over to Bristol-Myers Squibb's Videx (didanosine) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
